1. Home
  2. COGT vs SFL Comparison

COGT vs SFL Comparison

Compare COGT & SFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • SFL
  • Stock Information
  • Founded
  • COGT 2014
  • SFL 2003
  • Country
  • COGT United States
  • SFL Bermuda
  • Employees
  • COGT N/A
  • SFL N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • SFL Marine Transportation
  • Sector
  • COGT Health Care
  • SFL Consumer Discretionary
  • Exchange
  • COGT Nasdaq
  • SFL Nasdaq
  • Market Cap
  • COGT 1.1B
  • SFL 1.2B
  • IPO Year
  • COGT 2018
  • SFL N/A
  • Fundamental
  • Price
  • COGT $11.70
  • SFL $9.01
  • Analyst Decision
  • COGT Strong Buy
  • SFL Strong Buy
  • Analyst Count
  • COGT 9
  • SFL 1
  • Target Price
  • COGT $20.25
  • SFL $13.00
  • AVG Volume (30 Days)
  • COGT 1.8M
  • SFL 865.0K
  • Earning Date
  • COGT 08-05-2025
  • SFL 08-19-2025
  • Dividend Yield
  • COGT N/A
  • SFL 11.99%
  • EPS Growth
  • COGT N/A
  • SFL N/A
  • EPS
  • COGT N/A
  • SFL 0.41
  • Revenue
  • COGT N/A
  • SFL $852,590,000.00
  • Revenue This Year
  • COGT N/A
  • SFL N/A
  • Revenue Next Year
  • COGT N/A
  • SFL $3.20
  • P/E Ratio
  • COGT N/A
  • SFL $22.57
  • Revenue Growth
  • COGT N/A
  • SFL 6.58
  • 52 Week Low
  • COGT $3.72
  • SFL $6.78
  • 52 Week High
  • COGT $12.97
  • SFL $11.94
  • Technical
  • Relative Strength Index (RSI)
  • COGT 59.54
  • SFL 46.15
  • Support Level
  • COGT $10.38
  • SFL $9.02
  • Resistance Level
  • COGT $12.21
  • SFL $9.29
  • Average True Range (ATR)
  • COGT 0.53
  • SFL 0.22
  • MACD
  • COGT -0.16
  • SFL -0.05
  • Stochastic Oscillator
  • COGT 64.13
  • SFL 15.87

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About SFL SFL Corporation Ltd

SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.

Share on Social Networks: